Suggestions
Ryan Heit
Co-Founder and Vice President of Operations at Pacylex Pharmaceuticals
Ryan Heit is a seasoned professional with a diverse background in research, technology commercialization, business development, and angel investing.
With over a decade of experience in the angel investing space, Ryan has co-founded and invested in Valhalla Private Capital, showcasing his expertise in financing early stage companies.
Ryan has provided strategic business planning and company development for numerous early-stage, technology-based ventures in health-related fields during his tenure as the Director of the Merck Invention Accelerator and as an independent consultant.
Having served as the COO of Pacylex Pharmaceuticals, Ryan currently plays a pivotal role in driving operational excellence in the pharmaceutical industry.
Ryan's educational background includes a Master of Business Administration in Technology Commercialization, an MSc in Experimental Oncology, and a BSc in Biochemistry and Cell Biology, all from the University of Alberta.
Throughout his career, Ryan has held various key positions such as Co-Founder and Vice President of Operations at Pacylex Pharmaceuticals, Director at World in Need, and University of Alberta PSI Executive-in-Residence.
His affiliations with organizations like the Merck Invention Accelerator, Valhalla Private Capital, TEC Edmonton, and others highlight his wide-ranging expertise and involvement in the business and research landscapes.
Highlights
Nanostics announced today plans to develop a simple blood test to predict severe COVID-19 in SARS-CoV-2 patients, using their ClarityDX diagnostic platform. Nanostics will collaborate with the Canadian BioSample Repository in Alberta, and Century Clinical Research Inc. in Florida, to recruit COVID-19 patients to validate this novel test. ClarityDX COVID-19 test is forecasted to be ready for clinical validation studies in 6 to 8 weeks.
https://lnkd.in/gurwt9B
#COVID19 #COVID19Testing #Biotechnology
Please help me get the word out: The Merck Invention Accelerator is looking for our next cohort of applicants. We're looking for early-stage Canadian human and animal therapeutic companies to enter the program. Companies get access to Merck experts, capital and space. Details in the attached document. Please share!
